Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
An update from West Pharmaceutical Services ( (WST) ) is now available.
On July 24, 2025, West Pharmaceutical Services announced its second-quarter 2025 financial results, highlighting a 9.2% increase in net sales to $766.5 million and a rise in diluted EPS to $1.82. The company also raised its full-year 2025 net sales and adjusted-diluted EPS guidance, reflecting strong performance in high-value products and favorable foreign exchange rates. The Board approved a fourth-quarter dividend of $0.22 per share, to be paid on November 19, 2025.
The most recent analyst rating on (WST) stock is a Buy with a $345.00 price target. To see the full list of analyst forecasts on West Pharmaceutical Services stock, see the WST Stock Forecast page.
Spark’s Take on WST Stock
According to Spark, TipRanks’ AI Analyst, WST is a Neutral.
The overall stock score of 64 reflects solid financial performance and improved earnings guidance, which are offset by technical weakness and potential valuation concerns. Positive earnings call highlights are tempered by transitional challenges and market uncertainties.
To see Spark’s full report on WST stock, click here.
More about West Pharmaceutical Services
West Pharmaceutical Services, Inc. is a leading provider of innovative, high-quality injectable solutions and services, supporting drug developers in the containment and delivery of medicines. With over 10,000 team members across 50 sites worldwide, West delivers over 41 billion components and devices annually. The company is headquartered in Exton, Pennsylvania, and is listed on the New York Stock Exchange.
Average Trading Volume: 663,252
Technical Sentiment Signal: Sell
Current Market Cap: $16.33B
For detailed information about WST stock, go to TipRanks’ Stock Analysis page.